1st U.S. Hospitals Implement The Sirius Pintuition System

Surgical marker navigation system that is simple, precise, and affordable

Sirius Medical (“Sirius”) is pleased to announce that Ascension St. Vincent Carmel and Ascension St. Vincent Evansville are the first U.S. hospitals to implement the Pintuition System in their breast surgery programs. Both hospitals are part of the Ascension Health System in Indiana.

“I can’t think of a better technology to be launching at Evansville Surgical Associates,” says Joshua Aaron, MD, Evansville Surgical Associates. “By eliminating wire localization, you can take away the most stressful part of a breast surgery. The breast surgeons are excited to be an integral part of offering wire-free navigation to the women in our region.”

The Sirius Pintuition System is CE marked and FDA 510(k) cleared and over 3,000 procedures have been performed worldwide. The system is an intuitive, wire-free system with a multi-sensor probe and GPSDetect™ software that provides navigation with real-time directional guidance to locate tumors easily and accurately.

Charles Lackey, DO, diagnostic radiologist at Southern Indiana Imaging comments, “I am proud to be a part of implementing this innovative technology in Evansville, Indiana. In the past, a wire localization would need to be performed on the same day as surgery. With Pintuition, patients are seen prior to surgery for a simple and easy marker placement under radiographic guidance, it is a huge step forward for patient satisfaction.”

“We are hearing from our customers that the Sirius Pintuition System s reliability and navigation capabilities make the technology applicable for teaching and community hospitals alike as surgeons find it elegant and simple to use,” remarks Bram Schermers, CEO Sirius Medical. “This, combined with our affordable and innovative financial models, takes away the barriers in acquiring new technology and makes it easier for physicians and their institutions to implement a better standard of care with surgical navigation.”


Other news of interest can be found here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”